Sarah B. Miller

Sarah B. Miller

Auto-generated profile, based on publicly available information

Sarah B. Miller

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
SSSarah J. Shin
Sarah J. Shin
GCGeraldine O’sUllivan Coyne
Geraldine O’sUllivan Coyne
Shivaani KummarShivaani Kummar
Shivaani Kummar
SMSarah B. Miller
Sarah B. Miller
BJBarry C. Johnson
Barry C. Johnson
ACAlice Chen
Alice Chen
Purpose: We assessed the safety, maximum tolerated dose, and recommended phase 2 dose (RP2D), efficacy, pharmacokinetics, and pharmacodynamics of the nilotinib–paclitaxel combination in 44 patients with solid tumors. Patients and Methods: Paclitaxel was administered intravenously (days 1, 8, and 15), and nilotinib was administered twice daily orally beginning on cycle 1 day 2 (C1D2; escalation) or C1D3 (expansion) in 28-day cycles using a 3 + 3 dose escalation design. Pharmacodynamic biomarkers of drug action were assessed in paired tumor biopsies and circulating tumor cells at the RP2D. Results: The RP2D was 300 mg nilotinib twice daily with 80 mg/m2 paclitaxel. Grade 4 (Gr4) neutropenia and Gr3 rash, photosensitivity, and transaminase elevation were dose-limiting. The most common Gr3-4 toxicities were hematologic and hypophosphatemia; one patient (2%) experienced Gr3 peripheral neuropathy. Three patients [two with adult ovarian granulosa cell tumors (AOGCT) and one with endometrial carcinoma] had confirmed partial responses (cPR); the patients with AOGCT remained on study for 5 and 6+ years, and mesenchymal-like circulating tumor cells were measured prior to progression or during treatment holiday (patients 12 and 10, respectively). Conclusions: This study determined the maximum tolerated dose of this combination, demonstrated sustained cPRs in patients with AOGCT, and profiled molecular pharmacodynamic responses that will inform further mechanism-of-action studies. The rate of peripheral neuropathy suggests enhanced tolerability of this combination.

12 May 2026 in PLOS ONE
Verified
Journal Article
Open access
TNTony Navas
Tony Navas
ASApurva K. Srivastava
Apurva K. Srivastava
SLScott M. Lawrence
Scott M. Lawrence
MHMelinda G. Hollingshead
Melinda G. Hollingshead
SASergio Y. Alcoser
Sergio Y. Alcoser
RPRalph E. Parchment
Ralph E. Parchment
The HGF/SF (hepatocyte growth factor/scatter factor) receptor tyrosine kinase MET is overexpressed and/or activated in many tumors, providing therapeutic targets for antibody-drug conjugates and tyrosine kinase inhibitors. Reliable measurement of activated MET is fundamental for pharmacodynamic assessment of MET-targeted therapies and for expanded and proper use of such therapies in patients with tumors driven by activated MET with or without associated MET amplification or known activating mutations. To address the paucity of tools for directly measuring MET activation in tumor cells within patient biopsy specimens, we developed a robust, quantitative immunofluorescence microscopy assay to measure levels of pY 1235 MET and total MET in in vitro , in vivo , and patient tumor specimens. We validated this assay through assessment of MET inhibitor–treated preclinical models, peptide blocking experiments to demonstrate specificity, and concordance with corresponding measurements from the same specimens using a previously validated sandwich immunoassay of tumor lysates. Given the importance of plasma membrane-associated MET in initiating its canonical signaling cascades, as well as the demonstrated non-canonical signaling from nuclear localized MET in different tumor cell types and in response to various environmental stimuli, we developed assay capability to measure levels of pY 1235 MET and total MET within the plasma membrane or nucleus; these assays enable future explorations of the biological and clinical relevance of MET subcellular localization patterns. Finally, using tissue microarrays of over 50 resected tumor specimens from patients with colorectal carcinoma or non-small cell lung cancer, we demonstrated that tumor levels of pY 1235 MET do not always track total MET expression, suggesting that measurement of activated MET in tumor could hold potential as an independent biomarker to identify additional patients who might benefit from MET-directed targeted therapy—beyond those with tumor MET amplification, MET overexpression, or established MET-activating mutations.


3 June 2025
Verified
Other
Open access
SSSarah J. Shin
Sarah J. Shin
GCGeraldine O’sUllivan Coyne
Geraldine O’sUllivan Coyne
Shivaani KummarShivaani Kummar
Shivaani Kummar
SMSarah B. Miller
Sarah B. Miller
BJBarry C. Johnson
Barry C. Johnson
ACAlice Chen
Alice Chen
AUC values for paclitaxel and corresponding metabolites prior to Day 1 and after Day 8 coadministration with nilotinib

3 June 2025
Verified
Other
Open access
SSSarah J. Shin
Sarah J. Shin
GCGeraldine O’sUllivan Coyne
Geraldine O’sUllivan Coyne
Shivaani KummarShivaani Kummar
Shivaani Kummar
SMSarah B. Miller
Sarah B. Miller
BJBarry C. Johnson
Barry C. Johnson
ACAlice Chen
Alice Chen
Dose limiting toxicities for the nilotinib-paclitaxel combination

3 June 2025
Verified
Other
Open access
SSSarah J. Shin
Sarah J. Shin
GCGeraldine O’sUllivan Coyne
Geraldine O’sUllivan Coyne
Shivaani KummarShivaani Kummar
Shivaani Kummar
SMSarah B. Miller
Sarah B. Miller
BJBarry C. Johnson
Barry C. Johnson
ACAlice Chen
Alice Chen
All adverse events at least possibly attributed to study drugs